ACP Issues Recurrent Kidney Stone Prevention Guidelines

Share this content:
ACP Issues Recurrent Kidney Stone Prevention Guidelines
ACP Issues Recurrent Kidney Stone Prevention Guidelines

(HealthDay News) -- Increased fluid intake is recommended to prevent recurrent nephrolithiasis, with pharmacological monotherapy suggested for patients in whom increased fluid intake fails to reduce stone formation. These clinical practice guidelines were developed by the American College of Physicians (ACP) and published in the Nov. 4 issue of the Annals of Internal Medicine.

Amir Qaseem, M.D., Ph.D., from the ACP in Philadelphia, and colleagues developed guidelines on the comparative effectiveness and safety of dietary and pharmacological management of recurrent nephrolithiasis in adults. Data were collected from published literature. Symptomatic stone recurrence, pain, urinary tract obstruction with acute renal impairment, infection, procedure-related illness, emergency department visits, hospitalizations, quality of life, and end-stage renal disease were included as clinical outcomes assessed for this guideline.

The ACP recommends increased fluid intake throughout the day; recurrent nephrolithiasis can be prevented with fluid intake to achieve at least 2 L of urine per day (Grade: weak recommendation, low-quality evidence). For patients with active disease in whom increased fluid intake fails to reduce stone formation, the ACP recommends monotherapy with thiazide diuretic, citrate, or allopurinol (Grade: weak recommendation, moderate-quality evidence) to prevent recurrent nephrolithiasis.

"Increased fluid intake spread throughout the day can decrease stone recurrence by at least half with virtually no side effects," David Fleming, M.D., president of the ACP, said in a statement.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths